Synergistic Efficacy of Concurrent Treatment with Cilostazol and Probucol on the Suppression of Reactive Oxygen Species and Inflammatory Markers in Cultured Human Coronary Artery Endothelial Cells
The Korean Journal of Physiology and Pharmacology
; : 165-170, 2008.
Article
em En
| WPRIM
| ID: wpr-728591
Biblioteca responsável:
WPRO
ABSTRACT
In the present study, we aimed to identify the synergistic effects of concurrent treatment of low concentrations of cilostazol and probucol to inhibit the oxidative stress with suppression of inflammatory markers in the cultured human coronary artery endothelial cells (HCAECs). Combination of cilostazol (0.3~3micrometer) with probucol (0.03~0.3micrometer) significantly suppressed TNF-alpha-stimulated NAD(P)H-dependent superoxide, lipopolysaccharide (LPS)-induced intracellular reactive oxygen species (ROS) production and TNF-alpha release in comparison with probucol or cilostazol alone. The combination of cilostazol (0.3~3micrometer) with probucol (0.1~0.3micrometer) inhibited the expression of vascular cell adhesion molecule-1 (VCAM-1) and monocyte chemoattractant protein-1 (MCP-1) more significantly than did the monotherapy with either probucol or cilostazol. In line with these results, combination therapy significantly suppressed monocyte adhesion to endothelial cells. Taken together, it is suggested that the synergistic effectiveness of the combination therapy with cilostazol and probucol may provide a beneficial therapeutic window in preventing atherosclerosis and protecting from cerebral ischemic injury.
Palavras-chave
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Probucol
/
Tetrazóis
/
Monócitos
/
Fator de Necrose Tumoral alfa
/
Espécies Reativas de Oxigênio
/
Superóxidos
/
Estresse Oxidativo
/
Molécula 1 de Adesão de Célula Vascular
/
Quimiocina CCL2
/
Vasos Coronários
Tipo de estudo:
Prognostic_studies
Limite:
Humans
Idioma:
En
Revista:
The Korean Journal of Physiology and Pharmacology
Ano de publicação:
2008
Tipo de documento:
Article